Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 46
Filtrar
1.
Annu Rev Virol ; 10(1): 397-422, 2023 09 29.
Artigo em Inglês | MEDLINE | ID: mdl-37774124

RESUMO

Despite antiretroviral therapy (ART), people living with human immunodeficiency virus (HIV) (PLWH) continue to experience chronic inflammation and immune dysfunction, which drives the persistence of latent HIV and prevalence of clinical comorbidities. Elucidating the mechanisms that lead to suboptimal immunity is necessary for developing therapeutics that improve the quality of life of PLWH. Although previous studies have found associations between gut dysbiosis and immune dysfunction, the cellular/molecular cascades implicated in the manifestation of aberrant immune responses downstream of microbial perturbations in PLWH are incompletely understood. Recent literature has highlighted that two abundant metabolite families, short-chain fatty acids (SCFAs) and bile acids (BAs), play a crucial role in shaping immunity. These metabolites can be produced and/or modified by bacterial species that make up the gut microbiota and may serve as the causal link between changes to the gut microbiome, chronic inflammation, and immune dysfunction in PLWH. In this review, we discuss our current understanding of the role of the microbiome on HIV acquisition and latent HIV persistence despite ART. Further, we describe cellular/molecular cascades downstream of SCFAs and BAs that drive innate or adaptive immune responses responsible for promoting latent HIV persistence in PLWH. This knowledge can be used to advance HIV cure efforts.


Assuntos
Infecções por HIV , HIV-1 , Microbiota , Humanos , Ácidos e Sais Biliares/uso terapêutico , Qualidade de Vida , Latência Viral , Ácidos Graxos Voláteis/metabolismo , Ácidos Graxos Voláteis/uso terapêutico , Inflamação , Homeostase
2.
J Pediatr Nurs ; 73: 67-71, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-37647790

RESUMO

OBJECTIVES: A multimedia medication training program for parents and legal guardians of children with chronic kidney disease (CKD) aimed to improve comprehension CKD and general information about medications used in pediatric patients attending The Foundation for Children with Kidney Disease (FUNDANIER, Guatemala City). METHODS: A quasi-experimental study was carried out to measure the impact of the educational intervention on medication knowledge, at FUNDANIER from September to October 2019. Means and standard deviations was used to described test results. A Wilcoxon test was performed, to compare scores of pre and post-tests. Odds Ratio (OR) was used to determine if there was an improvement in the knowledge score before and after the intervention. Results There was significant improvement in knowledge scores knowledge before and after the intervention(27/35 versus 33/35, P < 0.005). Mestizo participants had higher odds of improvement before and after the intervention (OR 7, CI: 0.6-78). Parent-guardians with prior education, and who spoke Spanish had higher odds of improved knowledge scores (OR 3.2, CI:0.3-35; OR 1.1 CI: 0.1-14 respectively). CONCLUSION: Caregivers who participated in the educational workshop improved and retained information related to CKD comprehension and medications used. This study provides a model for educational modules that can be used, tested, and applied in other chronic disease settings in low to middle income countries. PRACTICE IMPLICATIONS: A culturally relevant multimedia CKD educational platform was effective in improving medication knowledge among parent/guardians of children with CKD in a low literacy setting.


Assuntos
Multimídia , Insuficiência Renal Crônica , Humanos , Criança , Guatemala , Cuidadores , Insuficiência Renal Crônica/terapia , Doença Crônica
3.
Fungal Genet Biol ; 168: 103823, 2023 10.
Artigo em Inglês | MEDLINE | ID: mdl-37453457

RESUMO

Filamentous fungi develop intricate hyphal networks that support mycelial foraging and transport of resources. These networks have been analyzed recently using graph theory, enabling the development of models that seek to predict functional traits. However, attention has focused mainly on mature colonies. Here, we report the extraction and analysis of the graph corresponding to Trichoderma atroviride mycelia only a few hours after conidia germination. To extract the graph for a given mycelium, a mosaic conformed of multiple bright-field, optical microscopy images is digitally processed using freely available software. The resulting graphs are characterized in terms of number of nodes and edges, average edge length, total mycelium length, hyphal growth unit, maximum edge length and mycelium diameter, for colonies between 8 h and 14 h after conidium germination. Our results show that the emerging hyphal network grows first by hyphal elongation and branching, and then it transitions to a stage where hyphal-hyphal interactions become significant. As a tangled hyphal network develops with decreasing hyphal mean length, the mycelium maintains long (∼2 mm) hyphae-a behavior that suggests a combination of aggregated and dispersed architectures to support foraging. Lastly, analysis of early network development in Podospora anserina reveals striking similarity with T. atroviride, suggesting common mechanisms during initial colony formation in filamentous fungi.


Assuntos
Hifas , Micélio , Fungos , Microscopia
4.
Ophthalmol Retina ; 7(1): 72-80, 2023 01.
Artigo em Inglês | MEDLINE | ID: mdl-35843486

RESUMO

PURPOSE: To investigate late vitreoretinal complications and visual outcomes in patients with regressed retinopathy of prematurity (ROP) with or without prior treatment. DESIGN: International, multicenter, noncomparative retrospective case series. PARTICIPANTS: We analyzed 264 eyes of 238 patients from 13 centers worldwide who developed vitreoretinal complications (retinal detachment [RD], vitreous hemorrhage [VH], or retinal break) ≥ 2 years after resolution of acute ROP. METHODS: Each participant was assigned to 1 of 3 groups (the RD, VH, and retinal break groups) according to their primary diagnosis. The average age at presentation, visual acuities, refractive error, axial length, gestational age, birth weight, acute ROP classification, prior treatments for acute ROP, postoperative visual acuity (VA), and concomitant eye conditions in the 3 groups were documented and compared. MAIN OUTCOME MEASURES: Clinical features and visual outcomes of late vitreoretinal complications in patients with regressed ROP. RESULTS: A total of 264 eyes of 238 patients were included. The prior acute ROP status was comparable among the 3 groups, except that the VH group had a higher proportion of patients with type 1 ROP (P = 0.03) and prior treatment (P < 0.001) than the other groups. The average age at presentation was earlier in the RD (20.3 ± 15.5 years) and VH (21.4 ± 18.9 years) groups than in the retinal break group (31.9 ± 18.2 years; P < 0.001). The retinal break group had the best presenting best-corrected VA, followed by the RD and VH groups (P < 0.001). Surgical intervention improved VA in both the RD and VH groups (both P < 0.05). The overall trend of VA was the most favorable in the retinal break group, followed by that in the VH and RD groups. Cicatricial changes in the fellow retina were observed in > 90% of patients with unilateral involvement. CONCLUSIONS: Infants with acute ROP remain at a high risk of vision-threatening complications throughout childhood and adulthood. Continual follow-up of patients with ROP is important. When severe complications, such as RD or VH, are detected, timely surgical intervention is necessary to ensure favorable visual outcomes in these patients.


Assuntos
Descolamento Retiniano , Perfurações Retinianas , Retinopatia da Prematuridade , Lactente , Recém-Nascido , Humanos , Adulto , Criança , Descolamento Retiniano/diagnóstico , Descolamento Retiniano/etiologia , Descolamento Retiniano/cirurgia , Perfurações Retinianas/cirurgia , Hemorragia Vítrea/diagnóstico , Hemorragia Vítrea/etiologia , Retinopatia da Prematuridade/complicações , Retinopatia da Prematuridade/diagnóstico , Retinopatia da Prematuridade/cirurgia , Estudos Retrospectivos , Resultado do Tratamento , Seguimentos , Vitrectomia/efeitos adversos , Retina
5.
Artigo em Inglês | MEDLINE | ID: mdl-36498431

RESUMO

Improved life expectancy is increasing the number of older adults who suffer from motor-cognitive decline. Unfortunately, conventional balance exercise programs are not tailored to patients with cognitive impairments, and exercise adherence is often poor due to unsupervised settings. This study describes the acceptability and feasibility of a sensor-based in-home interactive exercise system, called tele-Exergame, used by older adults with mild cognitive impairment (MCI) or dementia. Our tele-Exergame is specifically designed to improve balance and cognition during distractive conditioning while a telemedicine interface remotely supervises the exercise, and its exercises are gamified balance tasks with explicit augmented visual feedback. Fourteen adults with MCI or dementia (Age = 68.1 ± 5.4 years, 12 females) participated and completed exergame twice weekly for six weeks at their homes. Before and after 6 weeks, participants' acceptance was assessed by Technology Acceptance Model (TAM) questionnaire, and participants' cognition and anxiety level were evaluated by the Montreal Cognitive Assessment (MoCA) and Beck Anxiety Inventory (BAI), respectively. Results support acceptability, perceived benefits, and positive attitudes toward the use of the system. The findings of this study support the feasibility, acceptability, and potential benefit of tele-Exergame to preserve cognitive function among older adults with MCI and dementia.


Assuntos
Disfunção Cognitiva , Demência , Feminino , Humanos , Idoso , Pessoa de Meia-Idade , Demência/psicologia , Disfunção Cognitiva/psicologia , Cognição , Exercício Físico/psicologia , Terapia por Exercício/métodos
6.
Sensors (Basel) ; 22(20)2022 Oct 20.
Artigo em Inglês | MEDLINE | ID: mdl-36298343

RESUMO

The study presents a novel approach to objectively assessing the upper-extremity motor symptoms in spinocerebellar ataxia (SCA) using data collected via a wearable sensor worn on the patient's wrist during upper-extremity tasks associated with the Assessment and Rating of Ataxia (SARA). First, we developed an algorithm for detecting/extracting the cycles of the finger-to-nose test (FNT). We extracted multiple features from the detected cycles and identified features and parameters correlated with the SARA scores. Additionally, we developed models to predict the severity of symptoms based on the FNT. The proposed technique was validated on a dataset comprising the seventeen (n = 17) participants' assessments. The cycle detection technique showed an accuracy of 97.6% in a Bland-Altman analysis and a 94% accuracy (F1-score of 0.93) in predicting the severity of the FNT. Furthermore, the dependency of the upper-extremity tests was investigated through statistical analysis, and the results confirm dependency and potential redundancies in the upper-extremity SARA assessments. Our findings pave the way to enhance the utility of objective measures of SCA assessments. The proposed wearable-based platform has the potential to eliminate subjectivity and inter-rater variabilities in assessing ataxia.


Assuntos
Ataxia Cerebelar , Ataxias Espinocerebelares , Dispositivos Eletrônicos Vestíveis , Humanos , Ataxias Espinocerebelares/diagnóstico , Ataxia Cerebelar/diagnóstico , Ataxia/diagnóstico , Extremidade Superior
7.
iScience ; 25(5): 104305, 2022 May 20.
Artigo em Inglês | MEDLINE | ID: mdl-35586066

RESUMO

Early Th17 responses are necessary to provide protection against Mycobacterium tuberculosis (Mtb). Mtb impedes Th17 polarization by restricting CD40 co-stimulatory pathway on dendritic cells (DCs). We previously demonstrated that engaging CD40 on DCs increased Th17 responses. However, the molecular mechanisms that contributed to Th17 polarization were unknown. Here, we identify the Notch ligand DLL4 as necessary for Th17 polarization and demonstrate that Mtb limits DLL4 on DCs to prevent optimal Th17 responses. Although Mtb infection induced only low levels of DLL4, engaging CD40 on DCs increased DLL4 expression. Antibody blockade of DLL4 on DCs reduced Th17 polarization in vitro and in vivo. In addition, we show that the Mtb Hip1 protease attenuates DLL4 expression on lung DCs by impeding CD40 signaling. Overall, our results demonstrate that Mtb impedes CD40-dependent DLL4 expression to restrict Th17 responses and identify the CD40-DLL4 pathways as targets for developing new Th17-inducing vaccines and adjuvants for tuberculosis.

8.
Gac Med Mex ; 158(M3): M1-M48, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-35350063

RESUMO

Acute myeloid leukemia (AML) comprises a heterogeneous group of hematopoietic cell neoplasms of myeloid lineage that arise from the clonal expansion of their precursors in the bone marrow, interfering with cell differentiation, leading to a syndrome of bone marrow failure. AML is a consequence of genetic and epigenetic changes (point mutations, gene rearrangements, deletions, amplifications, and arrangements in epigenetic changes that influence gene expression) in hematopoietic precursor cells, which create a clone of abnormal cells that are capable of proliferating but cannot differentiate into mature hematopoietic cells or undergo programmed cell death. The diagnosis requires more than 20% myeloid blasts in the bone marrow and certain cytogenic abnormalities. Treatment will depend on age, comorbidities, and cytogenetic risk among the most frequent.


La leucemia mieloide aguda (LMA) comprende un grupo heterogéneo de neoplasias de células hematopoyéticas de linaje mieloide que surgen de la expansión clonal de sus precursores en la médula ósea, interfiriendo con la diferenciación celular, lo que conlleva a un síndrome de falla medular. La LMA es una consecuencia de cambios genéticos y epigenéticos (mutaciones puntuales, rearreglos de genes, deleciones, amplificaciones y arreglos en cambios epigenéticos que influyen en la expression del gen) en las células hematopoyéticas precursoras, la cual crea una clona de células anormales que son capaces de proliferar, pero no se pueden diferenciar en células hematopoyéticas maduras ni sufrir una muerte celular programada. El diagnostic requiere más del 20% de blastos mieloides en médula ósea y ciertas anormalidades citogénicas. El tratamiento dependerá de la edad, comorbilidades, riesgo citogenético entre las más frecuentes.


Assuntos
Leucemia Mieloide Aguda , Diferenciação Celular , Consenso , Humanos , Leucemia Mieloide Aguda/diagnóstico , Leucemia Mieloide Aguda/genética , Leucemia Mieloide Aguda/terapia , México
9.
Neurol Sci ; 43(4): 2589-2599, 2022 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-34664180

RESUMO

OBJECTIVE: To explore the use of wearable sensors for objective measurement of motor impairment in spinocerebellar ataxia (SCA) patients during clinical assessments of gait and balance. METHODS: In total, 14 patients with genetically confirmed SCA (mean age 61.6 ± 8.6 years) and 4 healthy controls (mean age 49.0 ± 16.4 years) were recruited through the Massachusetts General Hospital (MGH) Ataxia Center. Participants donned seven inertial sensors while performing two independent trials of gait and balance assessments from the Scale for the Assessment and Rating of Ataxia (SARA) and Brief Ataxia Rating Scale (BARS2). Univariate analysis was used to identify sensor-derived metrics from wearable sensors that discriminate motor function between the SCA and control groups. Multivariate linear regression models were used to estimate the subjective in-person SARA/BARS2 ratings. Spearman correlation coefficients were used to evaluate the performance of the model. RESULTS: Stride length variability, stride duration, cadence, stance phase, pelvis sway, and turn duration were different between SCA and controls (p < 0.05). Similarly, sway and sway velocity of the ankle, hip, and center of mass differentiated SCA and controls (p < 0.05). Using these features, linear regression models showed moderate-to-strong correlation with clinical scores from the in-person rater during SARA assessments of gait (r = 0.73, p = 0.003) and stance (r = 0.90, p < 0.001) and the BARS2 gait assessment (r = 0.74, p = 0.003). CONCLUSION: This study demonstrates that sensor-derived metrics can potentially be used to estimate the level of motor impairment in patient with SCA quickly and objectively. Thus, digital biomarkers from wearable sensors have the potential to be an integral tool for SCA clinical trials and care.


Assuntos
Ataxia Cerebelar , Ataxias Espinocerebelares , Dispositivos Eletrônicos Vestíveis , Adulto , Idoso , Marcha/fisiologia , Humanos , Pessoa de Meia-Idade , Equilíbrio Postural/fisiologia , Ataxias Espinocerebelares/complicações , Ataxias Espinocerebelares/diagnóstico
10.
Arana-Luna, Luara L.; Alvarado-Ibarra, Martha; Silva-Michel, Luis G.; Morales-Maravilla, Adrián; González-Rubio, María del C.; Chávez-Aguilar, Lénica A.; Tena-Iturralde, María Fernanda; Mojica-Balceras, Liliana; Zapata-Canto, Nidia; Galindo-Delgado, Patricia; Miranda-Madrazo, María Raquel; Morales-Hernández, Alba E.; Silva-Vera, Karina; Grimaldo-Gómez, Flavio A.; Hernández-Caballero, Álvaro; Bates-Martin, Ramón A.; Álvarez-Vera, José L.; Tepepa-Flores, Fredy; Teomitzi-Sánchez, Óscar; Fermín-Caminero, Denisse J.; Peña-Celaya, José A. de la; Salazar-Ramírez, Óscar; Flores-Villegas, Luz V.; Guerra-Alarcón, Lidia V.; Leyto-Cruz, Faustino; Inclán-Alarcón, Sergio I.; Milán-Salvatierra, Andrea I.; Ventura-Enríquez, Yanet; Pérez-Lozano, Uendy; Báez-Islas, Pamela E.; Tapia-Enríquez, Ana L.; Palma-Moreno, Orlando G.; Aguilar-Luévano, Jocelyn; Espinosa-Partida, Arturo; Pérez-Jacobo, Luis F.; Rojas-Castillejos, Flavio; Ruiz-Contreras, Josué I.; Loera-Fragoso, Sergio J.; Medina-Coral, Jesús E.; Acosta-Maldonado, Brenda L.; Soriano-Mercedes, Emely J.; Saucedo-Montes, Erick E.; Valero-Saldana, Luis M.; González-Prieto, Susana G.; Nava-Villegas, Lorena; Hernández-Colin, Ana K.; Hernández-Alcántara, Areli E.; Zárate-Rodríguez, Pedro A.; Ignacio-Ibarra, Gregorio; Meillón-García, Luis A.; Espinosa-Bautista, Karla A.; Ledesma de la Cruz, Cindy; Barbosa-Loría, Diego M.; García-Castillo, Carolina; Balderas-Delgado, Carolina; Cabrera-García, Álvaro; Pérez-Zúñiga, Juan M.; Hernández-Ruiz, Eleazar; Villela-Peña, Atenas; Gómez Cortés, Sue Cynthia; Romero-Rodelo, Hilda; Garzón-Velásquez, Katheryn B.; Serrano-Hernández, Cristina; Martínez-Ríos, Annel; Pedraza-Solís, María Luisa; Martínez-Coronel, Jorge A.; Narváez-Davalos, Iris M.; García-Camacho, Alinka S.; Merino-Pasaye, Laura E.; Aguilar-Andrade, Carolina; Aguirre-Domínguez, Juan A.; Guzmán-Mera, Pedro G.; Delgado-de la Rosa, Elizabeth; Flores López, Perla E.; González-Aguirre, Lilia L.; Ramírez-Alfaro, Edgar M.; Vera-Calderón, Heidi; Meza-Dávalos, María Lizeth; Murillo-Cruz, Juan; Pichardo-Cepín, Yayra M.; Ramírez-Romero, Eva F..
Gac. méd. Méx ; 158(spe): M1-M51, ene. 2022. tab, graf
Artigo em Espanhol | LILACS-Express | LILACS | ID: biblio-1375542

RESUMO

resumen está disponible en el texto completo


Abstract Acute myeloid leukemia (AML) comprises a heterogeneous group of hematopoietic cell neoplasms of myeloid lineage that arise from the clonal expansion of their precursors in the bone marrow, interfering with cell differentiation, leading to a syndrome of bone marrow failure. AML is a consequence of genetic and epigenetic changes (point mutations, gene rearrangements, deletions, amplifications, and arrangements in epigenetic changes that influence gene expression) in hematopoietic precursor cells, which create a clone of abnormal cells that are capable of proliferating but cannot differentiate into mature hematopoietic cells or undergo programmed cell death. The diagnosis requires more than 20% myeloid blasts in the bone marrow and certain cytogenic abnormalities. Treatment will depend on age, comorbidities, and cytogenetic risk among the most frequent.

11.
Front Immunol ; 12: 740117, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-34759923

RESUMO

Tuberculosis (TB) remains one of the leading causes of death worldwide due to a single infectious disease agent. BCG, the only licensed vaccine against TB, offers limited protection against pulmonary disease in children and adults. TB vaccine research has recently been reinvigorated by new data suggesting alternative administration of BCG induces protection and a subunit/adjuvant vaccine that provides close to 50% protection. These results demonstrate the need for generating adjuvants in order to develop the next generation of TB vaccines. However, development of TB-targeted adjuvants is lacking. To help meet this need, NIAID convened a workshop in 2020 titled "Advancing Vaccine Adjuvants for Mycobacterium tuberculosis Therapeutics". In this review, we present the four areas identified in the workshop as necessary for advancing TB adjuvants: 1) correlates of protective immunity, 2) targeting specific immune cells, 3) immune evasion mechanisms, and 4) animal models. We will discuss each of these four areas in detail and summarize what is known and what we can advance on in order to help develop more efficacious TB vaccines.


Assuntos
Adjuvantes Imunológicos/uso terapêutico , Mycobacterium tuberculosis/fisiologia , Vacinas contra a Tuberculose/imunologia , Tuberculose/imunologia , Animais , Congressos como Assunto , Modelos Animais de Doenças , Humanos , Evasão da Resposta Imune , Imunidade , National Institute of Allergy and Infectious Diseases (U.S.) , Tuberculose/terapia , Estados Unidos
12.
Gac Med Mex ; 157(Suppl 2): S1-S16, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-34324483

RESUMO

El linfoma de Hodgkin (LH) se debe a la transformación clonal de células originadas en los linfocitos B, lo que genera las células binucleadas patognomónicas de Reed-Sternberg. El LH es una enfermedad de células B con una distribución bimodal, con mayor incidencia en la adolescencia y la tercera década de la vida y un segundo pico en personas mayores de 55 años. Las células del LH clásico habitualmente sufren una reprogramación de la expresión génica, ya que pierden la expresión de la mayoría de los genes típicos de las células B y han adquirido la expresión de múltiples genes que son típicos de otros tipos de células del sistema inmunitario. El algoritmo de tratamiento dependerá si se trata de LH clásico o de predominio linfocítico, si es un estadio temprano con marcadores de pronóstico desfavorables o no, el esquema inicial de manejo y si existe enfermedad voluminosa, entre las variables más relevantes.Hodgkin's lymphoma (HL) is due to the clonal transformation of cells originating from B lymphocytes, generating the pathognomonic binucleate Reed-Sternberg cells. HL is a B cell disease with a bimodal distribution, with higher incidence in adolescence and the third decade of life, showing a second peak in people over 55 years of age. Classic Hodgkin lymphoma cells routinely undergo gene expression reprogramming, as they lose the expression of most of the typical B-cell genes and acquire the expression of multiple genes that are typical of other types of cells in the immune system. The treatment algorithm will depend on whether it is classic or predominantly lymphocytic HL, if it is early stage with unfavorable prognostic markers or not, the initial management regimen, and whether there is bulky disease, among the most relevant variables.


Assuntos
Consenso , Doença de Hodgkin , Fatores Etários , Algoritmos , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Transformação Celular Neoplásica/patologia , Doença de Hodgkin/genética , Doença de Hodgkin/patologia , Doença de Hodgkin/terapia , Humanos , Imunoterapia/métodos , Linfoma Relacionado a AIDS/etiologia , México , Estadiamento de Neoplasias , Tomografia por Emissão de Pósitrons combinada à Tomografia Computadorizada , Prognóstico , Células de Reed-Sternberg/patologia
13.
Gac Med Mex ; 157(Supl 2): S1-S18, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-34196636

RESUMO

Hodgkin's lymphoma is due to the clonal transformation of cells originating from B lymphocytes, generating the pathognomonic binucleate Reed-Sternberg cells. Hodgkin's lymphoma is a B cell disease with a bimodal distribution, with higher incidence in adolescence and the third decade of life, showing a second peak in people over 55 years of age. Classic Hodgkin lymphoma cells routinely undergo gene expression reprogramming, as they lose the expression of most of the typical B-cell genes and acquire the expression of multiple genes that are typical of other types of cells in the immune system. The treatment algorithm will depend on whether it is classic or predominantly lymphocytic HL, if it is early stage with unfavorable prognostic markers or not, the initial management regimen, and whether there is bulky disease, among the most relevant variables.


El linfoma de Hodgkin (LH) se debe a la transformación clonal de células originadas en los linfocitos B, lo que genera las células binucleadas patognomónicas de Reed-Sternberg. El LH es una enfermedad de células B con una distribución bimodal, con mayor incidencia en la adolescencia y la tercera década de la vida y un segundo pico en personas mayores de 55 años. Las células del LH clásico habitualmente sufren una reprogramación de la expresión génica, ya que pierden la expresión de la mayoría de los genes típicos de las células B y han adquirido la expresión de múltiples genes que son típicos de otros tipos de células del sistema inmunitario. El algoritmo de tratamiento dependerá si se trata de LH clásico o de predominio linfocítico, si es un estadio temprano con marcadores de pronóstico desfavorables o no, el esquema inicial de manejo y si existe enfermedad voluminosa, entre las variables más relevantes.


Assuntos
Consenso , Doença de Hodgkin , Células de Reed-Sternberg , Distribuição por Idade , Algoritmos , Antineoplásicos/uso terapêutico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Expressão Gênica , Doença de Hodgkin/tratamento farmacológico , Doença de Hodgkin/epidemiologia , Doença de Hodgkin/genética , Doença de Hodgkin/patologia , Humanos , México , Estadiamento de Neoplasias , Tomografia por Emissão de Pósitrons combinada à Tomografia Computadorizada , Células de Reed-Sternberg/patologia
14.
Int Immunopharmacol ; 98: 107825, 2021 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-34116286

RESUMO

The chemokine receptor CCR5 has been implicated in COVID-19. CCR5 and its ligands are overexpressed in patients. The pharmacological targeting of CCR5 would improve the COVID-19 severity. We sought to investigate the role of the CCR5-Δ32 variant (rs333) in COVID-19. The CCR5-Δ32 was genotyped in 801 patients (353 in the intensive care unit, ICU) and 660 healthy controls, and the deletion was significantly less frequent in hospitalysed COVID-19 than in healthy controls (p = 0.01, OR = 0.66, 95%CI = 0.49-0.88). Of note, we did not find homozygotes among the patients, compared to 1% of the controls. The CCR5 transcript was measured in leukocytes from 85 patients and 40 controls. We found a significantly higher expression of the CCR5 transcript among the patients, with significant difference when comparing the non-deletion carriers (controls = 35; patients = 81; p = 0.01). ICU-patients showed non-significantly higher expression than no-ICU cases. Our study points to CCR5 as a genetic marker for COVID-19. The pharmacological targeting of CCR5 should be a promising treatment for COVID-19.


Assuntos
COVID-19/genética , Variação Genética , Receptores CCR5/genética , SARS-CoV-2/patogenicidade , Idoso , Idoso de 80 Anos ou mais , COVID-19/diagnóstico , COVID-19/virologia , Estudos de Casos e Controles , Feminino , Predisposição Genética para Doença , Interações Hospedeiro-Patógeno , Humanos , Unidades de Terapia Intensiva , Masculino , Pessoa de Meia-Idade , Admissão do Paciente , Fenótipo , Medição de Risco , Fatores de Risco , Índice de Gravidade de Doença
15.
Gac Med Mex ; 157(Suppl 1): S1-S35, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-33819260

RESUMO

Hemophilia is a hemorrhagic disorder with a sex-linked inherited pattern, characterized by an inability to amplify coagulation due to a deficiency in coagulation factor VIII (hemophilia A or classic) or factor IX (hemophilia B). Sequencing of the genes involved in hemophilia has provided a description and record of the main mutations, as well as a correlation with the various degrees of severity. Hemorrhagic manifestations are related to levels of circulating factor, mainly affecting the musculoskeletal system and specifically the large joints (knees, ankles, and elbows). This document is a review and consensus of the main genetic aspects of hemophilia, from the inheritance pattern to the concept of women carriers, physiopathology and classification of the disorder, the basic and confirmation studies when hemophilia is suspected, the various treatment regimens based on infusion of the deficient coagulation factor as well as innovative factor-free therapies and recommendations for the management of complications associated with treatment (development of inhibitors and/or transfusion-transmitted infections), or secondary to articular hemorrhagic events (hemophilic arthropathy). Finally, relevant reviews of clinical and treatment aspects of hemorrhagic pathology characterized by acquired deficiency of FVIII secondary to neutralized antibodies named acquired hemophilia.


La hemofilia es un trastorno hemorrágico con patrón de herencia ligado al sexo, caracterizado por una incapacidad en la amplificación de la coagulación ocasionada por la deficiencia del factor VIII (hemofilia A o clásica) o del factor IX (hemofilia B). La secuenciación de los genes involucrados en la hemofilia ha permitido la descripción y registro de las principales mutaciones, así como la correlación con los diversos grados de severidad. Las manifestaciones hemorrágicas se relacionan con los niveles de factor deficiente circulante, afectando principalmente al sistema musculoesquelético y en particular a las grandes articulaciones (rodillas, tobillos y codos). El presente documento hace una revisión y consenso de los principales aspectos genéticos de la hemofilia, desde el patrón de herencia y el concepto de mujeres portadoras, la fisiopatología y clasificación de la enfermedad, los estudios básicos y de confirmación ante la sospecha de hemofilia, y de los diversos esquemas de tratamiento basados en la infusión del factor de coagulación deficiente hasta las terapias innovadoras libres de factor, así como de las recomendaciones para el manejo de las complicaciones asociadas al tratamiento (desarrollo de inhibidores y/o infecciones transmitidas por transfusión) o secundarias a los eventos hemorrágicos a nivel articular (artropatía hemofílica). La parte final del documento revisa los aspectos clínicos y de tratamiento relevantes de una patología hemorragica caracterizada por la deficiencia adquirida del FVIII mediada por anticuerpos neutralizantes denominada hemofilia adquirida.


Assuntos
Hemofilia A , Algoritmos , Hemofilia A/diagnóstico , Hemofilia A/etiologia , Hemofilia A/terapia , México
16.
JAMA Ophthalmol ; 139(4): 441-448, 2021 Apr 01.
Artigo em Inglês | MEDLINE | ID: mdl-33630045

RESUMO

IMPORTANCE: Outcome data are limited regarding early experience with brolucizumab, the most recently approved anti-vascular endothelial growth factor (VEGF) agent for the treatment of neovascular age-related macular degeneration (nAMD). OBJECTIVE: To report clinical outcomes after intravitreous injection (IVI) of brolucizumab, 6 mg, for nAMD. DESIGN, SETTING, AND PARTICIPANTS: This retrospective case series conducted at 15 private or academic ophthalmological centers in the United States included all consecutive patients with eyes treated with brolucizumab by 6 retina specialists between October 17, 2019, and April 1, 2020. EXPOSURES: Treatment with brolucizumab IVI, 6 mg. MAIN OUTCOMES AND MEASURES: Change in mean visual acuity (VA) and optical coherence tomography parameters, including mean central subfield thickness and presence or absence of subretinal and/or intraretinal fluid. Secondary outcomes included ocular and systemic safety. RESULTS: A total of 172 eyes from 152 patients (87 women [57.2%]; mean [SD] age, 80.0 [8.0] years) were included. Most eyes (166 [96.5%]) were not treatment naive, and 65.7% of these eyes (109 of 166) were switched from the prior anti-VEGF agent because of persistent fluid detected on optical coherence tomography scans. Study eyes received a mean (SD) of 1.46 (0.62) brolucizumab IVIs. The mean (SD) VA prior to starting brolucizumab was a 64.1 (15.9) Early Treatment Diabetic Retinopathy Study (ETDRS) letter score (Snellen equivalent, 20/50) and was a 63.3 (17.2) ETDRS letter score (Snellen equivalent, 20/63) at the last study evaluation (mean difference, 0.8; 95% CI, -2.7 to 4.3; P = .65). When analyzed by number of brolucizumab IVIs, the presence or absence of fluid prior to starting brolucizumab, or the presence or absence of intraocular inflammation after receiving brolucizumab, there was no difference in mean VA prior to starting brolucizumab compared with after brolucizumab IVIs or at the final study evaluation. The mean (SD) central subfield thickness in all eyes prior to starting brolucizumab was 296.7 (88.0) µm and was 269.8 (66.5) µm at the last study examination (mean difference, 26.9 µm; 95% CI, 9.0-44.7 µm; P = .003). Intraocular inflammation was reported in 14 eyes (8.1%) and was self-limited and resolved without treatment in almost half those eyes (n = 6). One previously reported eye (0.6%) had occlusive retinal vasculitis and severe loss of vision. CONCLUSIONS AND RELEVANCE: In this analysis of brolucizumab IVI for nAMD, VA remained stable, with a reduction in central subfield thickness. Intraocular inflammation events ranged from mild with spontaneous resolution to severe occlusive retinal vasculitis in 1 eye.


Assuntos
Retinopatia Diabética , Degeneração Macular , Vasculite Retiniana , Uveíte , Degeneração Macular Exsudativa , Idoso de 80 Anos ou mais , Inibidores da Angiogênese/efeitos adversos , Anticorpos Monoclonais Humanizados , Retinopatia Diabética/tratamento farmacológico , Feminino , Humanos , Inflamação/tratamento farmacológico , Injeções Intravítreas , Degeneração Macular/induzido quimicamente , Degeneração Macular/diagnóstico , Degeneração Macular/tratamento farmacológico , Masculino , Ranibizumab/uso terapêutico , Vasculite Retiniana/diagnóstico , Estudos Retrospectivos , Tomografia de Coerência Óptica/métodos , Uveíte/diagnóstico , Degeneração Macular Exsudativa/induzido quimicamente , Degeneração Macular Exsudativa/diagnóstico , Degeneração Macular Exsudativa/tratamento farmacológico
17.
Gac Med Mex ; 157(Supl 1): S1-S37, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-33588427
19.
López-Arroyo, José L.; Pérez-Zúñiga, Juan M.; Merino-Pasaye, Laura E.; Saavedra-González, Azucena; Alcivar-Cedeño, Luisa María; Álvarez-Vera, José Luis; Anaya-Cuellar, Irene; Arana-Luna, Luara L.; Ávila-Castro, David; Bates-Martín, Ramón A.; Cesarman-Maus, Gabriela; Chávez-Aguilar, Lénica A.; Peña-Celaya, José A. de la; Espitia-Ríos, María E.; Estrada-Domínguez, Patricia; Fermín-Caminero, Denisse; Flores-Patricio, Willy; García Chávez, Jaime; García-Lee, María T.; González-Pérez, María del Carmen; González-Rubio, María del Carmen; González-Villareal, María Guadalupe; Ramírez-Moreno, Fabiola; Hernández-Colin, Ana K.; Hernández-Ruiz, Eleazar; Herrera-Olivares, Wilfrido; Leyto-Cruz, Faustino; Loera-Fragoso, Sergio; Martínez-Ríos, Annel; Miranda-Madrazo, María R.; Morales-Hernández, Alba; Nava-Villegas, Lorena; Orellana-Garibay, Juan J.; Palma-Moreno, Orlando G.; Paredes-Lozano, Eugenia P.; Peña-Alcántara, Paula; Pérez-Lozano, Uendy; Pichardo-Cepín, Yayra M.; Reynoso-Pérez, Ana Carolina; Rodríguez-Serna, Mishel; Rojas-Castillejos, Flavio; Romero-Rodelo, Hilda; Ruíz-Contreras, Josué I.; Segura-García, Adela; Silva-Vera, Karina; Soto-Cisneros, Paulina M.; Tapia-Enríquez, Ana L.; Tavera-Rodríguez, Martha G.; Teomitzi-Sánchez, Óscar; Tepepa-Flores, Fredy; Valencia-Rivas, María D.; Valle-Cárdenas, Teresa; Varela-Constantino, Ana; Javier-Morales, Adrián; Martínez-Ramírez, Mario A.; Tena-Cano, Sergio; Terrazas-Marín, Ricardo; Vilchis-González, Shendel P.; Villela-Peña, Atenas; Mena-Zepeda, Verónica; Alvarado Ibarra, Martha.
Gac. méd. Méx ; 157(supl.1): S1-S37, feb. 2021. tab, graf
Artigo em Espanhol | LILACS-Express | LILACS | ID: biblio-1375490

RESUMO

resumen está disponible en el texto completo


Abstract Hemophilia is a hemorrhagic disorder with a sex-linked inherited pattern, characterized by an inability to amplify coagulation due to a deficiency in coagulation factor VIII (hemophilia A or classic) or factor IX (hemophilia B). Sequencing of the genes involved in hemophilia has provided a description and record of the main mutations, as well as a correlation with the various degrees of severity. Hemorrhagic manifestations are related to levels of circulating factor, mainly affecting the musculoskeletal system and specifically the large joints (knees, ankles and elbows). This document is a review and consensus of the main genetic aspects of hemophilia, from the inheritance pattern to the concept of women carriers, physiopathology and classification of the disorder, the basic and confirmation studies when hemophilia is suspected, the various treatment regimens based on infusion of the deficient coagulation factor as well as innovative factor-free therapies and recommendations for the management of complications associated with treatment (development of inhibitors and/or transfusion transmitted infections) or secondary to articular hemorrhagic events (hemophilic arthropathy). Finally, relevant reviews of clinical and treatment aspects of hemorrhagic pathology charachterized by acquired deficiency of FVIII secondary to neutralized antibodies named acquired hemophilia.

20.
Gac. méd. Méx ; 157(supl.2): S1-S18, feb. 2021. tab, graf
Artigo em Espanhol | LILACS-Express | LILACS | ID: biblio-1375492

RESUMO

Resumen El linfoma de Hodgkin (LH) se debe a la transformación clonal de células originadas en los linfocitos B, lo que genera las células binucleadas patognomónicas de Reed-Sternberg. El LH es una enfermedad de células B con una distribución bimodal, con mayor incidencia en la adolescencia y la tercera década de la vida y un segundo pico en personas mayores de 55 años. Las células del LH clásico habitualmente sufren una reprogramación de la expresión génica, ya que pierden la expresión de la mayoría de los genes típicos de las células B y han adquirido la expresión de múltiples genes que son típicos de otros tipos de células del sistema inmunitario. El algoritmo de tratamiento dependerá si se trata de LH clásico o de predominio linfocítico, si es un estadio temprano con marcadores de pronóstico desfavorables o no, el esquema inicial de manejo y si existe enfermedad voluminosa, entre las variables más relevantes.


Abstract Hodgkin's lymphoma is due to the clonal transformation of cells originating from B lymphocytes, generating the pathognomonic binucleate Reed-Sternberg cells. Hodgkin's lymphoma is a B cell disease with a bimodal distribution, with higher incidence in adolescence and the third decade of life, showing a second peak in people over 55 years of age. Classic Hodgkin lymphoma cells routinely undergo gene expression reprogramming, as they lose the expression of most of the typical B-cell genes and acquire the expression of multiple genes that are typical of other types of cells in the immune system. The treatment algorithm will depend on whether it is classic or predominantly lymphocytic HL, if it is early stage with unfavorable prognostic markers or not, the initial management regimen, and whether there is bulky disease, among the most relevant variables.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...